← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 2013Last known activity
Dec 10, 2019
Defunct as of Apr 29, 2021
Timeline
2010s
- Jun 1, 2011
MedDay Pharmaceuticals— Founded
2020s
- Apr 29, 2021
MedDay Pharmaceuticals— Defunct
Drugs by trial phase (2 distinct, 10 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Adrenoleukodystrophy
- Amyotrophic Lateral Sclerosis
- Charcot-Marie-Tooth Disease
- Hereditary Sensory and Motor Neuropathy
- Motor Neuron Disease
- Multiple Sclerosis
- Nerve Compression Syndromes
- Neuritis
- Optic Neuritis
- Peripheral Nervous System Diseases
- Polyneuropathies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Renal Insufficiency
- Sclerosis
- Tooth Diseases
Recent trials (15)
- NCT04223232Lead sponsorPhase 1Dec 10, 2019
- NCT04168723Lead sponsorPhase 1Nov 11, 2019
- NCT04252417Lead sponsorPhase 1Oct 11, 2019
- NCT04252430Lead sponsorPhase 1Oct 9, 2019
- NCT02936037Study directorPhase 3Dec 1, 2016
- NCT02936037Lead sponsorPhase 3Dec 1, 2016
- NCT02967679Lead sponsorPhase 1/Phase 2Sep 1, 2016
- NCT02967679Study directorPhase 1/Phase 2Sep 1, 2016
- NCT03114215Lead sponsorPhase 2Jun 29, 2016
- NCT02961803Study directorPhase 2/Phase 3Oct 1, 2014
- NCT02961803Lead sponsorPhase 2/Phase 3Oct 1, 2014
- NCT02220933Study directorPhase 3Oct 1, 2013
- NCT02220244Study directorPhase 3Oct 1, 2013
- NCT02220244Lead sponsorPhase 3Oct 1, 2013
- NCT02220933Lead sponsorPhase 3Oct 1, 2013
Details
- Founded
- Paris, FR Jun 1, 2011
- Last known activity
- Dec 10, 2019